Highest-materiality recent filing
Hemab appoints Keli Walbert to board and audit committee effective Sept 24, 2026
Keli Walbert elected Class I director, term expiring at 2027 annual meeting; also joins Audit Committee.
Hemab Q2 net loss $24.2M; FDA clears sutacimig Phase 3 in Glanzmann thrombasthenia
Net loss $24.2M ($0.80/share) vs $12.2M ($12.91/share) YoY; cash $457.5M, runway into 2029.
Hemab reports Q1 net loss $22.7M; completes $346.7M IPO, gets BTD for sutacimig
Net loss Q1 2026: $22.7M ($23.98/share) vs $15.3M ($16.18/share) YoY.
Director Laura Tadvalkar resigns from Hemab Therapeutics board effective May 8, 2026
Laura Tadvalkar, Ph.D., resigned as a member of the Board, effective May 8, 2026.
Hemab Therapeutics completes IPO of 19.3M shares at $18.00, raising $346.7M
IPO of 19,262,500 shares at $18.00 per share, including full exercise of underwriter option for 2,512,500 shares.
On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Hemab Therapeutics Holdings, Inc. (the “Company”), the Board elected Keli Walbert to serve as a member of the Board, effective immediately.
On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the “Company”) of her decision to resign as a member of the Company’s board of directors (the “Board”), effective immediately.
Max materiality 0.85 · Median 0.80 · Most common event leadership